Study details
Enrolling now
Transnasal Sphenopalatine Ganglion Block for Acute Subarachnoid Hemorrhage Headache
University of California, Davis
NCT IDNCT06621329ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2/3
Target enrollment
40
Study length
about 2 years
Ages
18–100
Locations
1 site in CA
About this study
Researchers are testing a transnasal sphenopalatine ganglion block as an addition to standard pain medication for reducing headache severity in people with acute subarachnoid hemorrhage. The trial also looks at whether this intervention can reduce the need for opioids during hospitalization and after discharge.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Transnasal sphenopalatine ganglion block
PhasePhase 2/Phase 3
Primary goalNumerical pain rating scale
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low8%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Endpoints
Primary: Numerical pain rating scale